Clinical Pharmacokinetics

, Volume 20, Issue 2, pp 114–122 | Cite as

Clinical Pharmacology of Valpromide

  • Meir Bialer
Drug Disposition


Valpromide has been used as an antiepileptic and antipsychotic drug for the past 25 years in several European countries. Unlike its corresponding acid, valproic acid, whose pharmacokinetics have been quite extensively reviewed, and despite years of clinical use, it appears that no reviews have been written on the pharmacokinetics of valpromide. This article summarises and analyses its pharmacokinetics from various aspects, with a special emphasis on the differences between valpromide and valproic acid.

In humans, valpromide is a prodrug of valproic acid. Despite their chemical similarity, the pharmacokinetics of the 2 drugs in humans are quite distinct. Compared with valproic acid, valpromide has a very short half-life (mean ± SD: 0.84 ± 0.33h; n = 6), a high clearance value (70 ± 31 L/h) and a large volume of distribution (75 ± 13L). Despite its rapid biotransformation to valproic acid, valpromide has some special characteristics, such as its inhibition of the enzyme epoxide hydrolase which is responsible for the metabolism of carbamazepine-10,11-epoxide. This review discusses the pharmacokinetics of valpromide, the interactions between it and other drugs such as carbamazepine and amitriptyline, and its antiepileptic and antipsychotic activities.


Valproic Acid Amitriptyline Antipsychotic Drug Anticonvulsant Activity Styrene Oxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetic evaluation of novel sustained release dosage forms of valproic acid. Biopharmaceutics and Drug Disposition 6: 401–411, 1985bCrossRefGoogle Scholar
  2. Bialer M, Friedman M, Rubinstein A. A rapid GLC assay for monitoring valproic acid and valpromide in plasma. Journal of Pharmaceutical Sciences 73: 991–993, 1984aPubMedCrossRefGoogle Scholar
  3. Bialer M, Haj-Yehia A, Barzaghi N, Pisani F, Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. European Journal of Clinical Pharmacology 38: 289–291, 1990PubMedCrossRefGoogle Scholar
  4. Bialer M, Rubinstein A. A comparative study on the pharmacokinetics of valpromide after intravenous administration in dogs. Journal of Pharmacy and Pharmacology 35: 607–609, 1983PubMedCrossRefGoogle Scholar
  5. Bialer M, Rubinstein A. Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharmaceutics and Drug Disposition 5: 177–183, 1984CrossRefGoogle Scholar
  6. Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. International Journal of Pharmaceutics 23: 25–33, 1985aCrossRefGoogle Scholar
  7. Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy subjects. European Journal of Clinical Pharmacology 27: 501–503, 1984bPubMedCrossRefGoogle Scholar
  8. Billig H, Ziv E, Bar-On H, Bialer M. The disposition of valpromide in rats and in the isolated perfused rat liver. Drug Metabolism and Disposition 18: 238–244, 1990PubMedGoogle Scholar
  9. Bouchard JM, Pujol M. Thérapeutique méconnue ou 4 grandes indications du Dépamide. Information Psvchiatry 51: 341–346, 1975Google Scholar
  10. Carraz G, Darbon M, Lebreton S, Beriel H. Propriétés pharma-codynamiques de l’acide n-dipropylacétique et de ses dérives. Quatrième mémoire: le n-dipropyl acétamide. Therapy 19: 469–475, 1964Google Scholar
  11. Emrich HM. Anti-epileptic agents: II. Diphenylhydantoin, dipro-pylacetamide, valproate and progabide. In Johnson (Ed.) Lithium combination treatment, pp. 156–163, Krager, Basel, 1987Google Scholar
  12. Favel P, Cartier J, Gratadou JP, Gratadou G. Depamide® in the treatment of epilepsy, a clinical trial. Epilepsia 14: 329–334, 1973PubMedCrossRefGoogle Scholar
  13. Garrel S, Carraz G, Borselli S. Action anti-épileptique et éléctroencéphalographique du Dépamide. CR. Congress Psychiatry Neurology Langue Française 64: 1030–1033, 1964Google Scholar
  14. Gibaldi M, Perrier D. (Eds) Pharmacokinetics, 2nd ed., pp. 319–353, Marcel Dekker, New York, 1982Google Scholar
  15. Gugler R, von Unruh E. Clinical pharmacokinetics of valproic acid. Clinical Pharmacokinetics 5: 67–83, 1980PubMedCrossRefGoogle Scholar
  16. Haidukewych D, John G. Chronic valproic acid and coantiepi-leptic drug therapy and incidences of increases in serum liver enzymes. Therapeutic Drug Monitoring 8: 407–410, 1986PubMedCrossRefGoogle Scholar
  17. Haj-Yehia A, Bialer M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. Journal of Pharmaceutical Sciences 77: 831–834, 1988PubMedCrossRefGoogle Scholar
  18. Haj-Yehia A, Bialer M. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharmaceutical Research 6: 683–689, 1989PubMedCrossRefGoogle Scholar
  19. Kerr BM, Levy RH. Carbamazepine epoxide. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 505–520, Raven Press, New York, 1989Google Scholar
  20. Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clinical Pharmacology and Therapeutics 46: 82–93, 1989PubMedCrossRefGoogle Scholar
  21. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clinical Pharmacology and Therapeutics 21: 736–743, 1977PubMedGoogle Scholar
  22. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In Emrich et al. (Eds) Anticonvulsants in affective disorders, pp. 33–44, Experta Medica, Amsterdam. 1984Google Scholar
  23. Lambert PA, Carraz G, Borselli S. Action neuropsychotrope d’un novel anti-épileptique: le Dépamide. Annales Médico-Psychologiques 1: 707–710, 1966Google Scholar
  24. Lambert PA, Venaud G. Utilisation du valpromide en thérapeutique psychiatrique. L’Encéphale 13: 367–373, 1987PubMedGoogle Scholar
  25. Lemperiere T, Feline A, Gutman A. Le Dépamide: problè mes posés par son association à d’autres psychotropes. Annales de Médecine Interne 123: 783–786, 1972PubMedGoogle Scholar
  26. Lesur A. Le valpromide, une molécule a redécouvrir. Synapse 36: 81–88, 1987Google Scholar
  27. Levy RH. Valproate: modem perspectives. Epilepsia 25 (Suppl. 1): S1–S77. 1984CrossRefGoogle Scholar
  28. Levy RH, Kerr BM, Loiseau P, Guyst M, Wilensky AJ. Inhibition of carbamazepine epoxide elimination by valpromide and valproic acid. Epilepsia 27: 592. 1986Google Scholar
  29. Levy RH, Koch KM. Drug interactions with valproic acid. Drugs 24: 543–546, 1982PubMedCrossRefGoogle Scholar
  30. Levy RH, Shen DD. Valproate: absorption, distribution, and excretion. In Levy et al. (Eds) Antiepileptic drugs, 3rd ed., pp. 583–599. Raven Press, New York, 1989Google Scholar
  31. Loscher W, Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24: 427–435, 1985PubMedCrossRefGoogle Scholar
  32. Mairlot F. Analyses de résultats obtenus avec le Dépamide chez des enfants atteints d’instabilité psychomotorice (hyperkiné-sie). Acta Psychiatrica Belgica 79: 201–224, 1979Google Scholar
  33. Meijer JWA, Binnie CB, Debets RM, Van Parys JAP, De Beer-Pawlikowski NKB. Possible hazard of valpromide-carbamaz-epine combination therapy in epilepsy. Lancet 1: 802, 1984PubMedCrossRefGoogle Scholar
  34. Musolino R, Gallitto G, Morgante L, Pisani F, Di Perri R. The antiepileptic properties of n-dipropylacetamidc. Acta Neurol-ogica 2: 107–114, 1980Google Scholar
  35. Oreskovic D, Whitlon PS, Pericic D, Markovic Z, Bulal M. Brain gamma-aminobutyric acid and protection from picrotoxininduced convulsions following treatment with di-n-propyla-cetamide and di-n-propylacetic acid. Periodicam Biologorium 89: 17–20, 1987Google Scholar
  36. Oxley J, Hedges A, Makki KA, Monka A, Richens A. Lack of enzyme inducing effect of sodium valproate. British Journal of Clinical Pharmacology 8: 189–190, 1978CrossRefGoogle Scholar
  37. Pacifici GM, Franchi M, Bencini C, Rane A. Valpromide inhibits human epoxide hydrolase. British Journal of Clinical Pharmacology 22: 269–274, 1986PubMedCrossRefGoogle Scholar
  38. Pacifici GM, Rane A. Valpromide but not sodium hydrogen di-valproate inhibits epoxide hydrolase in human liver. Pharmacology and Toxicology 60: 237–238, 1987PubMedCrossRefGoogle Scholar
  39. Pacifici GM, Tomson T, Bertilsson L, Rane A. Valpromide/carbamazepine and risk of teratogenicity. Lancet 2: 397–398, 1985CrossRefGoogle Scholar
  40. Pascalis G, Delisle JP, Maes L. Le Dépamide, en dehors des accès maniaques pars. CR. Congress Psychiatry Neurology Langue Française 71: 1026–1034, 1971Google Scholar
  41. Pisani F, D’Agastano AA, Fazio A, Oteri G, Pimerano G, et al. Increased dipropylacetic acid bioavailability from dipropyla-cetamide by food. Epilepsia 23: 115–121, 1982aPubMedCrossRefGoogle Scholar
  42. Pisani F, Di Perri R, Nistico G. Rapid quantitation of N-dipro-pyl-acetamide in human plasma by gas-liquid chromatography. Journal of Chromatography 174: 231–233, 1979PubMedCrossRefGoogle Scholar
  43. Pisani F, Di Perri R. Some clinical and pharmacological aspects of n-dipropylacetamide. Italian Journal of Neurological Sciences 4: 245–249, 1980Google Scholar
  44. Pisani F, Fazio A, Oteri G, Di Perri R. Dipropylacetic acid plasma levels: diurnal fluctuations during chronic treatment with dipropylacelamide. Therapeutic Drug Monitoring 3: 297–301, 1981PubMedCrossRefGoogle Scholar
  45. Pisani F, Fazio A, Oteri G, Di Perri R. A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats. Journal of Pharmacy and Pharmacology 34: 45–46, 1982bPubMedCrossRefGoogle Scholar
  46. Pisani F, Fazio A, Oteri G, Ruello G, Gitto C, et al. Sodium valproate and valpromide: differential interaction with carb-amazepine in epileptic patients. Epilepsia 27: 548–552, 1986PubMedCrossRefGoogle Scholar
  47. Pisani F, Fazio A, Oteri G, Spira A, Perucca E, et al. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. British Journal of Clinical Pharmacology 25: 611–613, 1988PubMedCrossRefGoogle Scholar
  48. Porter RJ, Cereghino JJ, Gladding CD, Hessie BJ, Kupferberg HJ, et al. Antiepileptic drug development program. Cleveland Clinical Quarterly 5: 293–305, 1984Google Scholar
  49. Puzynski S. Valproic acid amide as a prophylactic agent in schizoaffective disorders. Psychopharmacology Bulletin 20: 151–159, 1984PubMedGoogle Scholar
  50. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. Journal of Affective Disorders 6: 115–121, 1984PubMedCrossRefGoogle Scholar
  51. Reekers-Ketting JJ, Van der Kleijn E, Leliveld BA, Schobben AFAM, Vree TB. Pharmacokinetics of di-propyl acetate (Depakine) in different dosage forms in man and rhesus monkey. Pharmaceutisch Weekblad 110: 1232–1236, 1975Google Scholar
  52. Richou H, Hug R, Doublet J. Le Dépamide, un psychotrope nor-molhymique (pour de nouveauz schémas thérapeutiques). Annales Médico-Psychologiques 2: 676–684, 1973PubMedGoogle Scholar
  53. Riva R, Albani F, Olivi F, Pantaloni M, Baruzzi A. Quantitative determination of n-dipropylacetamide in plasma of epileptic patients by gas-liquid chromatography with nitrogen-selective detection. Journal of Chromatography and Biomedical Applications 233: 371–374, 1982CrossRefGoogle Scholar
  54. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed., pp. 17–32, Lea & Febiger, Philadelphia. 1989Google Scholar
  55. Rubinstein A, Bialer M, Friedman M, Raz I, Abramsky O. A combined approach to control valproic acid release via novel drug delivery systems of valpromide: a kinetic and a pharmacokinetic study. Journal of Controlled Release 4: 33–38, 1986CrossRefGoogle Scholar
  56. Schobben F. Valproic acid: pharmacokinetic aspects. British Journal of Clinical Practice Supplement 27: 48–51, 1983Google Scholar
  57. Semadeni GW. Étude clinique de l’effet normothymique du dipropylacetamide. Acta Psychiatrica Belgica 76: 458–466, 1976PubMedGoogle Scholar
  58. Stepansky W. A clinical study in the use of valmethamide, an anxiety reducing drug. Current Therapeutic Research 2: 144–149, 1960PubMedGoogle Scholar
  59. Vandel S, Bertschy G, Jounet JM, Allers G. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Therapeutic Drug Monitoring 10: 386–389, 1988PubMedCrossRefGoogle Scholar
  60. Vencovsky E. Prophylactic effect of dipropylacetamide by bipolar maniomelancholic psychosis. European Journal of Psychiatry 1: 28–30, 1987Google Scholar
  61. Vencovsky E, Soucek K, Kabes J. Prophylactic effect of dipropylacetamide in patients with bipolar affective disorder. In Emrich et al. (Eds) Anticonvulsants in affective disorder, pp. 66–67, Excerpta Medica, Amsterdam, 1984Google Scholar
  62. Whitton PS, Oreskovic D, Jernej B, Bulat M. Antiepileptic di-n-propylacetamide and di-n-propylacetic acid increase the noradrenaline turnover in the brain. Periodicum Biologorium 86: 231–234, 1984Google Scholar
  63. Whitton PS, Oreskovic D, Jernej B, Radacic M, Plavsic F, et al. Plasma level of dipropylacetamide and dipropylacetic acid and effect of these drugs on 5-hydroxytryptamine metabolism in mouse brain. Biomedicine and Pharmacotherapy 40: 191–193, 1986Google Scholar
  64. Whitton PS, Oreskovic D, Markovic Z, Skarpa D, Bulta M. Effect of the antiepileptic di-n-propylacetamide on 5-hydroxytryptamine turnover in the brain and 5-hydroxyindolacetic acid level in the cerebrospinal fluid. European Journal of Pharmacology 91: 57–62, 1983PubMedCrossRefGoogle Scholar
  65. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid- 1988. Clinical Pharmacokinetics 15: 367–389, 1988PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Meir Bialer
    • 1
  1. 1.Department of PharmacySchool of Pharmacy, Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations